ARDS - Aridis stock rises 6% as antibody cocktail AR-701 protects against Omicron in animal models

Pharmaceuticals (NASDAQ:ARDS) said both of its fully human monoclonal antibodies (mAbs) in the AR-701 cocktail neutralized the SARS-CoV-2 Omicron variant in in-vitro. In addition, both mAbs conferred complete protection against Omicron infected animals when given either parenterally or by intranasal administration. The company said the mAbs in the AR-701 cocktail, AR-720 and AR-703, neutralized all authentic SARS-CoV-2 beta, gamma, delta, epsilon, and Omicron variants in vitro. Aridis (ARDS) noted that both mAbs of AR-701, when used individually or in combination, conferred complete eradication of virus from Omicron infected mice and protection against disease pathology. "We believe these exciting animal efficacy results are the first of any COVID antibody program to show this level of broad reactivity and efficacy, including in Omicron infected models. Given large scale clinical data from others which showed mAbs are effective as a COVID-19 preventative treatment, we think that AR-701 is well positioned for pan-coronavirus prophylaxis"

For further details see:

Aridis stock rises 6% as antibody cocktail AR-701 protects against Omicron in animal models